BR112014015605A2 - método de reconstituição para formulações de proteína seca de alta concentração - Google Patents

método de reconstituição para formulações de proteína seca de alta concentração

Info

Publication number
BR112014015605A2
BR112014015605A2 BR112014015605A BR112014015605A BR112014015605A2 BR 112014015605 A2 BR112014015605 A2 BR 112014015605A2 BR 112014015605 A BR112014015605 A BR 112014015605A BR 112014015605 A BR112014015605 A BR 112014015605A BR 112014015605 A2 BR112014015605 A2 BR 112014015605A2
Authority
BR
Brazil
Prior art keywords
high concentration
dry protein
protein formulations
formulations
reconstitution
Prior art date
Application number
BR112014015605A
Other languages
English (en)
Inventor
John Macleod Andrew
Vos Jan
Original Assignee
Xstalbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xstalbio Ltd filed Critical Xstalbio Ltd
Publication of BR112014015605A2 publication Critical patent/BR112014015605A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)

Abstract

resumo "método de reconstituição para formulações de proteína seca de alta concentração" a presente invenção refere-se ao fornecimento de um novo método para a reconstituição de formulações secas que compreendem biomoléculas e, em particular, a formulações de proteína seca, e a produtos farmacêuticos ou veterinários adequados para a administração parenteral contendo formulações reconstituídas preparadas de acordo com o novo método da invenção.
BR112014015605A 2011-12-23 2012-12-24 método de reconstituição para formulações de proteína seca de alta concentração BR112014015605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1122430.0A GB201122430D0 (en) 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation
PCT/GB2012/053266 WO2013093525A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations

Publications (1)

Publication Number Publication Date
BR112014015605A2 true BR112014015605A2 (pt) 2017-07-04

Family

ID=45695059

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015605A BR112014015605A2 (pt) 2011-12-23 2012-12-24 método de reconstituição para formulações de proteína seca de alta concentração

Country Status (8)

Country Link
US (1) US20140308293A1 (pt)
EP (1) EP2793852A1 (pt)
JP (1) JP2015511129A (pt)
BR (1) BR112014015605A2 (pt)
CA (1) CA2859287A1 (pt)
GB (1) GB201122430D0 (pt)
IN (1) IN2014MN01381A (pt)
WO (1) WO2013093525A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313368D0 (en) 2013-07-26 2013-09-11 Xstalbio Ltd Novel Reconstitution devices
US20170274012A1 (en) * 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
US10143625B2 (en) 2015-03-17 2018-12-04 Recon Therapeutics, Inc. Pharmaceutical reconstitution
EP3500588A1 (en) 2016-08-17 2019-06-26 Boehringer Ingelheim International GmbH Process for the preparation of highly concentrated liquid formulations containing biomolecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178884A (en) * 1988-05-18 1993-01-12 Cryopharm Corporation Lyophilized and reconstituted red blood cell compositions
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations

Also Published As

Publication number Publication date
US20140308293A1 (en) 2014-10-16
WO2013093525A1 (en) 2013-06-27
IN2014MN01381A (pt) 2015-04-17
JP2015511129A (ja) 2015-04-16
GB201122430D0 (en) 2012-02-08
EP2793852A1 (en) 2014-10-29
CA2859287A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
PH12014501628A1 (en) Stabilized formulations containing anti-ang2 antibodies
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
CY1116311T1 (el) Συνθεσεις ινσουλινων υπερ-ταχειας δρασης
BR112016002614B8 (pt) Imunocitoquina e composição farmacêutica
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
BR112012029280A2 (pt) variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
WO2014004993A3 (en) Methods of reducing ldl-p
BR112013027963A2 (pt) "variante de subtilisina com atividade proteolítica, ácido nucleico, vetor de expressão, célula hospedeira, composição e método de limpeza".
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
EA201791850A1 (ru) Борсодержащие малые молекулы
EA200870264A1 (ru) Композиция антител
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4
BR112014010222A2 (pt) formulação de enzima líquida e processo para sua preparação
BR112014031841A2 (pt) formulação farmacêutica
AR077384A1 (es) Una formulacion farmaceutica inyectable de melfalano.
BR112014015605A2 (pt) método de reconstituição para formulações de proteína seca de alta concentração
BR112014004522A2 (pt) moduladores de pde10
BR112013003899A2 (pt) domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]